Brentuximab vedotin with gemcitabine for paediatric and young adult patients with relapsed or refractory Hodgkin's lymphoma (AHOD1221): a Children's Oncology Group, multicentre single-arm, phase 1

Brentuximab vedotin with gemcitabine for paediatric and young adult patients with relapsed or refractory Hodgkin's lymphoma (AHOD1221): a Children's Oncology Group, multicentre single-arm, phase 1–2 trial

Published:2018-09 Issue:9 Volume:19 Page:1229-1238
ISSN:1470-2045
Container-title:The Lancet Oncology
language:en
Short-container-title:The Lancet Oncology

Author:

Cole Peter D,McCarten Kathleen M,Pei Qinglin,Spira Menachem,Metzger Monika L,Drachtman Richard A,Horton Terzah M,Bush Rizvan,Blaney Susan M,Weigel Brenda J,Kelly Kara M

Funder

National Institutes of Health to the Children's Oncology Group

NCTN Operations Center

NCTN Statistics & Data Center

Publisher

Elsevier BV

Subject

Oncology

Reference29 articles.

1. Hodgkin's lymphoma in children and adolescents: improving the therapeutic index;Kelly;Blood,2015

2. Stratification of treatment intensity in relapsed pediatric Hodgkin's lymphoma;Harker-Murray;Pediatr Blood Cancer,2014

3. Results of a pivotal phase II study of brentuximab vedotin for patients with relapsed or refractory Hodgkin's lymphoma;Younes;J Clin Oncol,2012